NASDAQ:CDNA CareDx - CDNA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. $9.08 +0.13 (+1.45%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.92▼$9.2950-Day Range$8.83▼$17.6152-Week Range$8.10▼$40.42Volume594,513 shsAverage Volume1.48 million shsMarket Capitalization$487.32 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CareDx MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside76.2% Upside$16.00 Price TargetShort InterestBearish9.87% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.42Based on 4 Articles This WeekInsider TradingSelling Shares$492,669 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.12) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector285th out of 995 stocksMedical Laboratories Industry11th out of 26 stocks 4.2 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, CareDx has a forecasted upside of 76.2% from its current price of $9.08.Amount of Analyst CoverageCareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.87% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CareDx has recently increased by 4.51%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 1.3 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CareDx this week, compared to 4 articles on an average week.Search InterestOnly 15 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $492,669.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of CareDx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.12) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CareDx (NASDAQ:CDNA) StockCareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.Read More Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address CDNA Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comCareDx, Inc (NASDAQ:CDNA) Receives $16.00 Consensus PT from BrokeragesMarch 23, 2023 | finance.yahoo.comCareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant AssociationMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 11, 2023 | finance.yahoo.comCareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call TranscriptMarch 11, 2023 | businesswire.comCAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNAMarch 7, 2023 | finance.yahoo.comThe American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant SurveillanceMarch 6, 2023 | finance.yahoo.comCareDx Update Regarding Raymond James & Associates’ ConferenceMarch 6, 2023 | finance.yahoo.comCareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors ConferenceMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 3, 2023 | businesswire.comCareDx Comments on MolDX Publication of New Billing and Coding ArticleMarch 1, 2023 | finance.yahoo.comCareDx Full Year 2022 Earnings: In Line With ExpectationsMarch 1, 2023 | finance.yahoo.comCareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient SummitFebruary 27, 2023 | finance.yahoo.comBaron Discovery Fund Believes CareDx (CDNA) Will Reward Investors for PatienceFebruary 27, 2023 | finance.yahoo.comCareDx Reports Fourth Quarter and Full Year 2022 ResultsFebruary 22, 2023 | finance.yahoo.comCareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation MeetingFebruary 21, 2023 | finance.yahoo.comCareDx to Report Fourth Quarter and Full Year 2022 Financial ResultsFebruary 16, 2023 | finance.yahoo.comEarnings Preview: CareDx (CDNA) Q4 Earnings Expected to DeclineFebruary 16, 2023 | finance.yahoo.comCareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem MeetingsJanuary 26, 2023 | finance.yahoo.comCareDx (NASDAQ:CDNA) delivers shareholders splendid 20% CAGR over 5 years, surging 9.8% in the last week aloneJanuary 26, 2023 | finance.yahoo.comJACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical PracticeJanuary 11, 2023 | finance.yahoo.comCareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter SymposiumJanuary 9, 2023 | finance.yahoo.comCareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022December 21, 2022 | finance.yahoo.comNew ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant PatientsDecember 12, 2022 | seekingalpha.comCareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)December 6, 2022 | finance.yahoo.comCareDx Announces $50 Million Stock Repurchase ProgramDecember 1, 2022 | finance.yahoo.comIndependent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant SurveillanceNovember 17, 2022 | finance.yahoo.comHere's Why CareDx (CDNA) Could be Great Choice for a Bottom FisherSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address CDNA Company Calendar Last Earnings10/28/2021Today3/27/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees633Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+76.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,610,000.00 Net Margins-23.81% Pretax Margin-23.69% Return on Equity-17.33% Return on Assets-14.09% Debt Debt-to-Equity RatioN/A Current Ratio5.11 Quick Ratio4.85 Sales & Book Value Annual Sales$321.79 million Price / Sales1.51 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book1.13Miscellaneous Outstanding Shares53,670,000Free Float51,205,000Market Cap$487.32 million OptionableOptionable Beta1.03 Key ExecutivesReginald SeetoPresident, Chief Executive Officer & DirectorAbhishek JainChief Financial & Accounting OfficerAmitabh ShuklaSenior Vice President-TechnologySham DholakiaSenior VP-Medical Affairs & Clinical OperationsRobert N. WoodwardVice President-Research & DevelopmentKey CompetitorsProgenityNASDAQ:PROGCastle BiosciencesNASDAQ:CSTLInvitaeNYSE:NVTACelcuityNASDAQ:CELCBiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsReginald SeetoSold 2,819 sharesTotal: $44,765.72 ($15.88/share)Macquarie Group Ltd.Sold 719,373 shares on 2/21/2023Ownership: 1.649%State of Wisconsin Investment BoardSold 3,254 shares on 2/15/2023Ownership: 0.094%Algert Global LLCBought 790 shares on 2/15/2023Ownership: 0.087%E Fund Management Co. Ltd.Bought 5,382 shares on 2/15/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions CDNA Stock - Frequently Asked Questions Should I buy or sell CareDx stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CDNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDNA, but not buy additional shares or sell existing shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price forecast for 2023? 5 equities research analysts have issued 12-month target prices for CareDx's shares. Their CDNA share price forecasts range from $9.00 to $25.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 76.2% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2023? CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 20.4% and is now trading at $9.08. View the best growth stocks for 2023 here. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) released its earnings results on Thursday, October, 28th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.21. The company earned $75.60 million during the quarter, compared to analysts' expectations of $74.11 million. CareDx had a negative trailing twelve-month return on equity of 17.33% and a negative net margin of 23.81%. CareDx's revenue for the quarter was up 41.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.06) EPS. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has CareDx issued on next quarter's earnings? CareDx issued an update on its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $328.00 million-$338.00 million, compared to the consensus revenue estimate of $338.42 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). What is CareDx's stock symbol? CareDx trades on the NASDAQ under the ticker symbol "CDNA." Who are CareDx's major shareholders? CareDx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.56%), ArrowMark Colorado Holdings LLC (7.48%), Sumitomo Mitsui Trust Holdings Inc. (4.79%), Nikko Asset Management Americas Inc. (4.79%), Bamco Inc. NY (3.84%) and Gagnon Securities LLC (2.79%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CareDx's stock price today? One share of CDNA stock can currently be purchased for approximately $9.08. How much money does CareDx make? CareDx (NASDAQ:CDNA) has a market capitalization of $487.32 million and generates $321.79 million in revenue each year. The company earns $-76,610,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. How many employees does CareDx have? The company employs 633 workers across the globe. How can I contact CareDx? CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450. This page (NASDAQ:CDNA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.